alprolix
pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 2000 [iu]; - powder for infusion - 2000 iu - active: eftrenonacog alfa 2000 [iu] excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)
alprolix
pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 250 [iu]; - powder for infusion - 250 iu - active: eftrenonacog alfa 250 [iu] excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)
alprolix
pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 3000 [iu]; - powder for infusion - 3000 iu - active: eftrenonacog alfa 3000 [iu] excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)
alprolix
pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 500 [iu]; - powder for infusion - 500 iu - active: eftrenonacog alfa 500 [iu] excipient: histidine mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)
benefix
pfizer new zealand limited - nonacog alfa 3000 [iu] (+/- 10% overage) - powder for injection with diluent - 3000 iu - active: nonacog alfa 3000 [iu] (+/- 10% overage) excipient: glycine histidine polysorbate 80 sucrose sodium chloride water for injection - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.
rixubis
takeda new zealand limited - nonacog gamma 100 iu/ml equivalent to 500 iu/vial; - powder for injection - 100 iu/ml - active: nonacog gamma 100 iu/ml equivalent to 500 iu/vial excipient: calcium chloride dihydrate histidine mannitol polysorbate 80 sodium chloride sucrose water for injection - · routine prophylaxis of bleeding episodes in patients with haemophilia b · treatment & prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) · peri-operative management in patients with haemophilia b
rixubis
takeda new zealand limited - nonacog gamma 200 iu/ml equivalent to 1000 iu/vial; - powder for injection - 200 iu/ml - active: nonacog gamma 200 iu/ml equivalent to 1000 iu/vial excipient: calcium chloride dihydrate histidine mannitol polysorbate 80 sodium chloride sucrose water for injection - · routine prophylaxis of bleeding episodes in patients with haemophilia b · treatment & prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) · peri-operative management in patients with haemophilia b
rixubis
takeda new zealand limited - nonacog gamma 400 iu/ml equivalent to 2000 iu/vial; - powder for injection - 400 iu/ml - active: nonacog gamma 400 iu/ml equivalent to 2000 iu/vial excipient: calcium chloride dihydrate histidine mannitol polysorbate 80 sodium chloride sucrose water for injection - · routine prophylaxis of bleeding episodes in patients with haemophilia b · treatment & prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) · peri-operative management in patients with haemophilia b
rixubis
takeda new zealand limited - nonacog gamma 50 iu/ml equivalent to 250 iu/vial; - powder for injection - 50 iu/ml - active: nonacog gamma 50 iu/ml equivalent to 250 iu/vial excipient: calcium chloride dihydrate histidine mannitol polysorbate 80 sodium chloride sucrose water for injection - · routine prophylaxis of bleeding episodes in patients with haemophilia b · treatment & prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) · peri-operative management in patients with haemophilia b
rixubis
takeda new zealand limited - nonacog gamma 600 iu/ml equivalent to 3000 iu/vial; - powder for injection - 600 iu/ml - active: nonacog gamma 600 iu/ml equivalent to 3000 iu/vial excipient: calcium chloride dihydrate histidine mannitol polysorbate 80 sodium chloride sucrose water for injection - · routine prophylaxis of bleeding episodes in patients with haemophilia b · treatment & prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) · peri-operative management in patients with haemophilia b